1. The analysis of the antibody response in autoimmune thyroid disease has followed several historical trends. It was the investigation of thyroid-reactive antibody that allowed the initial characterization of the three principle thyroid autoantigens, thyroglobulin, thyroid peroxidase and the thyroid stimulating hormone receptor. 2. Analysis can be grouped under two broad areas: analysis of the physiological and pathological effects of the antibody, and analysis of the structure of the antibodies themselves. This review will focus on the latter. 3 . Within recent years there has been a great increase in knowledge of thyroid-reactive antibody structure, principally through the adoption of phage display combinatorial library methodologies. While this latter technique has established some general principles for antibodies to thyroglobin and especially thyroid peroxidase, there is still a substantial gap in our knowledge of the antibody response to the thyroid stimulating hormone receptor. 4 . Thyroid peroxidase antibodies have a relatively restricted V-region usage, and there is a correlation between the V-regions used and the epitope on thyroid peroxidase bound. In particular the V, light chain, VK1(012), is associated with reactivity to one epitope. 5. The purpose of this review is to bring together the latest results concerning the molecular analysis of the antibody response in autoimmune thyroid disease, to highlight areas of ignorance and conflict, and to discuss the methods adopted to circumvent the problems associated with analysis of the antibody response.
GENERAL PRINCIPLES: WHAT IS BEING LOOKED FOR, HOW AND WHY?
The study of autoantibody (AAb) sequences has several goals, leading ultimately to a better understanding of the development of the autoimmune response and the potential for sequence specific modulation of the immune response [l] . While T-cells are undoubtedly heavily involved in the development of the autoimmune response, and may themselves provide the key to specific modulation, they are outside the scope of this review. Similarly, much work has been carried out analysing the immune response to thyroid autoantigens in animal models, but limitations on space preclude any discussion here. Readers are directed to another recent review [2] for discussion of these topics.
The basic steps involved in the analysis of the AAb response are the isolation of AAb-secreting cells or phage, sequencing of the genes involved and further characterization of the AAb reactivity, including determination of specificity, affinity and epitope recognition. The first of these three steps is methodologically the most difficult. Two principal methods have been employed for the determination of the AAb repertoire. The first, immortalization of B-cells, usually by heterohybridoma formation involving the fusion of human B-cells with one of a number of (generally murine) partners and limiting dilution, results in a monoclonal antibody (mAb)-secreting B-cell clone [3] . Despite great advances in the techniques involved, the practical difficulties of B-cell immortalization are what has, until recently, resulted in such a paucity of described thyroid-reactive antibody (Ab) sequences. Although thyroidreactive Ab-secreting clones were first described in reactive Abs was carried out in 1989 and 1991 for thyroglobin (Tg) mAbs [5, 61, with sequence data following in 1995 [7] , and in 1992 for a single thyroid peroxidase (TPO) Ab [8] . The number of thyroid-reactive Ab sequences derived in this way is still small. The second method for isolating the AAb repertoire is through phage display libraries, in which Ab heavy-and light-chain regions (in random combinations) are cloned and expressed in bacteriophage, with selection of sequences by screening with antigen (Fig. 1) ; this has been the subject of recent reviews [9, 101 . Phage display techniques have greatly increased the number of described thyroidreactive Ab sequences.
Access to a high-quality source of antigen is another important factor determining the likelihood of success. High-purity Tg has been available for a number of years, and particularly since its cloning, human TPO of high quality and purity has also been available in quantity (reviewed in [ll] ). The thyroid stimulating hormone receptor (TSH-R) is more problematical; thyroid cells express relatively small amounts of the TSH-R, with a background of Tg and TPO expression, making their use for the cloning of TSH-R-specific phage impractical. Although bioassays using the TSH-R are sensitive, difficulties in B-cell cloning have limited the number of clones RNA is isolated from the clinical sample and converted into cDNA. Using Ig family-specific primers, PCR is used to amplify the Ig chains present in the sample. These are then used to construct a library of heavy and light chains in a phagemid vector. The heavy-and light-chain genes encode a Fab fragment that is covalently attached to a protein in the phage coat. Phage are selected with antigen, non-specific phage discarded, and antigen-selected phage used to infect bacteria. Selected phage are grown from the infected bacteria and then re-selected with antigen. After several rounds of selection, phagemid DNA from the infected host is 'solubilized', in which the covalent attachment between the Fab and the phage coat is removed. This allows analysis and characterization of soluble Fab fragments.
Adapted from [9] with permission from the publisher.
available for analysis by this route. The quality of the TSH-R protein used is also a problem; like most thyroid-reactive Abs, TSH-R-specific Abs predominantly recognize the intact (native) molecule, and do not interact well with denatured or poor quality preparations (reviewed in [12] ). The cloning of the TSH-R has not proved as useful as that of TPO; bacterial preparations are likely to be in the wrong conformation for Ab recognition, but eukaryotic expression has also resulted in structural problems, which are only now becoming better understood [13] . This is discussed in greater detail below. The analysis of Ab sequences defines the amount of restriction in the Ab response, both within and between patients. A restricted Ab response would be more amenable to specific immunomodulation; for example, to therapy using anti-idiotypic Abs [l] . Patterns of immunoglobulin (Ig) variable (V) region usage may also have a bearing on the course of autoimmune thyroid disease (AITD), because the development of disease may be influenced by the inheritance of specific germline V-regions [14, 151, either directly or through the interplay of antigenspecific B-cells and T-cells . Which V-regions are dominant in the response of a particular patient is also likely to be determined by which epitopes are targeted by the Ab response; this has been best characterized in the TPO Ab response, in which patterns of restriction to different epitopes are beginning to emerge [19, 201 . The presence of somatic hypermutation and, especially, their patterns within patients at different times, can tell us a great deal about the developing specificity of the Ab response. Analysis of the germline progenitors of sequences that have been subjected to somatic hypermutation is also important. Defining the germline progenitor of an isolated Ig sequence is typically performed by analysis of nucleotide homology. To perform this task rigorously requires isolation of the candidate germline region(s) from the patient, and confirmation by sequencing that the germline region identified by homology searches is the most likely progenitor. As discussed below, the reactivity of these germline progenitor sequences may be more relevant to the events initiating disease.
ANTIBODIES TO THYROGLOBULIN

Epidemiology and pathogenicity
Tg Abs were the first human AAbs to be delineated [21] , and for many years haemagglutination remained the method of choice for their detection. Recently ELISA and sensitive RIAs have been developed which provide more quantitative data and are more sensitive [22] . However, it seems unlikely that these have any major clinical advantage over haemagglutination, as the main information required from testing Tg Abs is whether or not they are present and, if present, whether at a high or low level, without need for more formal quantification.
Obviously, this is not the case in research studies, where the new assays have proved invaluable.
The type of assay employed determines the frequency of Tg Abs in various study populations: around 5-10% of healthy women are Ab positive by haemagglutination or ELISA, whereas 15-20% are positive by RIA [22, 231 . The frequency in men is 10-fold lower. In such individuals, there is a close association with focal thyroiditis, and a proportion will progress to overt hypothyroidism over a 20year period [23] . Tg Abs are found in the majority of patients with autoimmune hypothyroidism and around 30-50% of patients with Graves' disease (GD), but almost always in association with TPO Abs. In contrast, TPO Abs may be positive without Tg Abs being positive, indicating that testing for TPO Abs alone may be a cost-effective strategy for screening for thyroid autoimmunity [24] . The increased frequency of Tg (and TPO) Abs seen in patients with associated autoimmune disorders (e.g. type 1 diabetes, Addison's disease, pernicious anaemia, coeliac disease, collagen vascular disorders) carries the same significance as in healthy controls, indicating focal thyroiditis and a group at risk of developing hypothyroidism.
The pathogenic role of Tg Abs remains unclear.
They do not fix complement, due to the wide spacing between the major epitopes on Tg which prevents IgG cross-linking. They may play a role in Ab-dependent cell-mediated cytotoxicity, as this can be demonstrated in vitro [25] . Some Tg Abs also bind to TPO, so-called TGPO Abs [26] , and these may reflect a degree of antigenic cross-reactivity which could explain the frequent association between Tg and TPO autoreactivity.
Molecular analysis of the Tg Ab repertoire
Perhaps surprisingly, molecular analysis of the Ab. response to Tg has been somewhat limited to date.. Whereas the ability to purify Tg in quantity has been available for decades, the lack of a convincing pathological role for these Abs has led to only a modest interest in their molecular structure. This is in contrast to the situation with TSH-R Abs, for which considerable effort has been made to isolate Abs typical of those occurring in AITD, but with the lack of pursed protein with physiological structure hampering such attempts. Historically, the molecular analysis of Tg Abs, like that of TPO and TSH-R Abs, has followed three phases: analysis of subclassand light-chain-restriction of Tg Abs in patient serum, production of Tg Ab-secreting hybridomas and the use of combinatorial libraries. Initial analysis indicated that the response was not subclass restricted, and later work has confirmed this (reviewed in [2] ).
Binding and sequencing analysis of IgG and IgM Tg Abs has been reported from peripheral blood, thyroid tissue and cervical (thyroid draining) lymph node B-cells in several patients with Hashimoto's thyroiditis (HT), using both hybridoma and phage display techniques [5] [6] [7] [27] [28] [29] . No sequences have been reported from patients with GD to date. Several general points can be made concerning these sequences. Firstly, a restricted IgG subclass pattern is evident in the sequences that have been reported. IgG2 is often the most common subclass present in patients with HT, but IgGl and IgG4 nevertheless form a substantial part of the response [25, 301 . However, the majority of the IgG Tg Ab sequences reported have come from the IgG2 subclass. As Tg Abs from different subclasses have been reported to bind to different Tg epitopes [31] , and might therefore be expected to be encoded by different Ig variable/(diversity)/joining (V/(D)/J) combinations, only a fraction of the potential patient Tg Ab repertoire must be represented in reports to date. From these reports, it would appear that the Tg Ab response is not significantly restricted.
Four IgM Tg Abs have been reported [28] ; others, by virtue of cross-reactivity to Tg, have also been described (e.g. [32] ). The pathological significance of IgM subclass Tg Abs is less clear than for IgG Tg Abs. Autoreactive IgM Abs, often referred to as natural AAbs, are typically polyreactive and of low affinity [33] . Although still debated, it is a possibility that high-affinity IgG Tg Abs are derived from natural IgM Abs, as described in other diseases [34, 351. The IgM Tg Abs reported may therefore represent precursor sequences to high-affinity IgG Tg Abs; indeed two (F1.l and T1.l) show evidence of somatic hypermutation in both heavy-and lightchain sequences, associated with increased relative affinity for Tg and indicative of antigen-specific selection [28] . In addition, the sequences of the IgM Tg Abs are similar to those of IgG Tg Abs. However, all reported IgM Tg Abs display polyreactivity to Tg from other species and other unrelated antigens, and the importance of these and other IgM Tg Abs is therefore equivocal.
There is evidence for somatic hypermutation in many of the Tg Ab sequences reported. Because the sequences of the corresponding patient germline V-regions have not been defined, these differences may be due to differences in germline V-region sequence. However, the presence of sometimes substantial differences between reported germline V-region and Tg Ab sequences, and the pattern of replacement and silent mutations in complementarity determining regions (CDRs) and framework regions, suggests somatic hypermutation has occurred, thus indicating an antigen-driven immune response. A correlation between the amount of somatic hypermutation and the affinity of Tg Abs from the lymph node of a patient with HT has been described, emphasising this point [29] . The presence of somatic hypermutation is perhaps unsurprising, given both the presence of IgG Abs (which in itself suggests longevity of the immune response) and the chronic nature of AITD; patients have often suf-fered from disease for years before surgical removal of thyroid tissue, a common source of material for study.
Epitopes on Tg
For reasons of space, this topic will be restricted mainly to work concerning the cloned human Tg Ab repertoire; further discussion is available elsewhere [2] . There is no current consensus on the number of epitopes recognized by Abs to Tg. Although the Tg Ab response is somewhat heterogeneous, there is apparent restriction of most AITD patient-derived Tg Abs to two or three conformational epitopes [7, 361. The epitope recognition of only four of the Tg Abs described to date has been determined, with two clones each binding to two epitopes [7] , essentially confirming earlier comparative studies between human and murine mAb reactivities [6] . In contrast to the TPO Ab response, there is no sequence consensus between these clones and the epitope recognized. One way to determine epitope recognition is to inhibit the binding of patient sera using mAbs which react with single epitopes; in this way, the number and sites of epitopes can be established. Inhibition of patient serum Ab binding to Tg using mAbs indicates a heterogeneous pattern of binding within both HT and GD patients, with most patient sera being blocked completely by the mAb 3C42, or by a combination of the mAbs 3'32 and VB5 [7] . A minority of patients showed greater reactivity towards the epitope defined by VB5 than that defined by 3C42, but overall, both patient groups behaved similarly.
Alternative methods for determining epitope specificity, for example analysing patient serum binding to tryptic peptides generated from Tg, suggests that one epitope is recognized preferentially by GD sera and another by HT sera, although there is overlap [36] . Peptide sequence data for one of these tryptic peptides has been reported, indicating that at least one AAb epitope is at the C-terminal end of Tg [37] , confirming similar results using other mapping methods [38] . However, data from the tryptic peptide mapping method are still to be confirmed by other groups, and it has not yet been established how the various epitope mapping methods compare. In addition, comparative mapping using human mAbs and the several available panels of murine Tg mAbs has been limited to date (e.g. [6] ).
ANTIBODIES TO THYROID PEROXIDASE
Epidemiology and pathogenicity
The epidemiology of TPO Abs roughly matches that of Tg Abs, discussed above, but TPO Abs are more frequently detected, especially in GD. Interestingly, sera positive for gastric parietal cell Abs, but negative for conventional TPO Abs, recognize a linear peptide containing the C2 and C21 epitopes (discussed below), and this cross-reactivity may relate to the frequent concurrence of AITD and pernicious anaemia [39] .
Unlike Tg Abs, TPO Abs can fix complement and there is abundant complement activation in the thyroids of patients with AITD [40] , suggesting that this is a major pathogenetic mechanism for thyroid injury. However, the TPO antigen is sequestered, being localized to the follicular luminal border of thyroid cells, and therefore access to TPO by Abs presumably depends on some other type of injury, such as T-cell-mediated damage, before TPO Abs can participate in Ab-dependent cell-mediated cytotoxicity [25] . Finally, some TPO Abs can inhibit TPO enzymic function in vitro, which could contribute to hypothyroidism, but the importance of this has been questioned (reviewed in [2] ).
Molecular analysis and TPO Ab repertoire restriction
The Ab response to TPO is the best characterized amongst the thyroid autoantigens, and has been the subject of a number of excellent recent reviews [lo-12, 411. The largest: number of Ig V-region sequences encoding TPO Abs have come from combinatorial libraries made from the thyroids of GD patients [19, [42] [43] [44] [45] [46] [47] , with three Fab fragments (Fab) from the thyroid of a HT patient [48] , and only one report of a fusion-derived mAb 18, 491. We have recently analysed 37 IgGic anti-TPO Fab from two patients with HT (R.S. McIntosh, M.S. Asghar, E.H Kemp, P.F. Watson, A. Gardas, J.P. Banga and A.P. Weetman, unpublished work). These were derived from both thyroid and cervical (thyroid-draining) lymph node tissue, the latter being a likely site of somatic hypermutation of the TPO Ab response.
The great majority of sequences reported to date have been derived from IgGlc libraries. IgGA TPO Ab sequences are rare; only four have been described, detected at a frequency about one tenth that of IgGlc sequences [46, 471. Screening of our IgGA libraries failed to detect any TPO-reactive Fab, even after five rounds of antigen selection; this observation was consistent with the small amount of detectable IgG3, TPO Abs in serum from the patients. A much lower apparent titre of IgGA than IgGic TPO Abs appears to be a common pattern in patients with AITD [25, 46, 501. The similarity in the repertoire of TPO Abs between patients with HT and GD, and the restriction of the response to a single major immunodominant region on native TPO, indicates that the two repertoires may be considered together. The heavy chains are restricted mainly to members of the v H 1 and vH3 families; however, these are numerically the most common families, both in terms of numbers of germline regions and in the numbers of B-cells expressing rearranged VH segments in the adult repertoire [51, 521. Similarly, V,I and V,III family members, found in the vast majority of TPO Abs, are also the most common V, segments [53] . Despite this, certain V-regions are 'over-represented' in the repertoire described to date; in particular, Fab-containing sequences derived from vH1-2, VH~-3 and V,O12 (from the VKI family) have been isolated from a number of different patients. Usage of common J-segments is also frequent in TPO Abs, with the J H~, J H~ and J H~, and JK1, JK2 and JK4 segments also being the most commonly used in the adult B-cell repertoire [53-551. Therefore, although restricted, the TPO Ab repertoire appears to be formed from common elements from the total Ab repertoire, and recombination of a large number of germline segments might therefore be capable of conferring TPO reactivity. It is unclear what features of these common elements is responsible for conferring TPO reactivity.
The single V-region of most interest is the vK012 light-chain germline region. Not only is this element common in the TPO Ab repertoire, but it is also the region best correlated to epitope specificity (see below). However, further analysis of Fab fragments containing this V-region indicates that the presence of this element alone is not sufficient to cause TPO reactivity. Only 1 in 5000 phage containing the SP1.2 (V,012) light chain in combination with random patient SP library heavy chains bound to TPO [44] . In the Complementary experiment, 1 in 500 phage containing the SP1.2 heavy chain with random light chains bound to TPO, and all these phage contained the VK012 light chain, although in association with different J, regions [44] . Analysis of random clones from the SP light-chain library showed that 12 out of 14 were derived from vK012, indicating that only a small minority of VK012-containing sequences were able to bind TPO, at least in association with the SP1.2 heavy chain [56] .
The experiments described above also show another interesting feature of TPO-reactive Abs, the lack of 'promiscuity' between heavy-and light-chain sequences [9] . Promiscuity has been described in a number of experimental systems, and refers to the pairing of heavy chains with a number of different light chains, with no alteration of antigen specificity (reviewed in [9] ). It is highly suggestive of the dominance of the heavy chain in determining antigen specificity. Because sequences derived from V,012 form such a dominant feature of the known TPO Ab response, it is this segment that is also best represented in experiments concerning promiscuity, consciously designed or otherwise. The 'roulette' experiments of Portolano et al. [44] are the best, but not the only, example. As described above, only 1 in 5000 phage containing the SP1.2 light chain with random SP heavy chains bound to TPO [44] , and these heavy chains were either very similar to the originating heavy-chain sequence or derived from the same germline %-region. In the complementary experiment, TPO-selected phage containing the SP1.2 heavy chain with random light chains also contained the vK012 light chain, although in association with different J, regions [44] . In a second series of experiments, light and heavy chains from different TPO-reactive Fab were recombined artificially; none of the resulting hybrid Fab bound TPO [20] . Such experiments argue against heavy chain/ light chain promiscuity being a major factor in the TPO Ab response; indeed, it would appear that the light chain is perhaps the dominant chain in this response [20] .
In the TPO-reactive Fab from our laboratory, there was a clear division into two major groups. Despite both being from the VKI family, vK012 and VKL8 were always found in combination with dif- indeed, Rapoport's group has consistently found that there was rarely simple homology between known D segments and the junctions of their TPO Fab [19, [42] [43] [44] [45] [46] [47] . In addition, the two heavy chains from IgG Tg Abs, for which nucleotide sequences are available in public databases (MH52 [27] and heavy chain [29] ), and IgM sequences from TSH-R Abs [60] , also show evidence for D-D fusion.
However, a number of factors argue against D-D fusion playing a critical role in the development of the TPO Ab response. Most importantly, in a study of heavy chains chosen at random from a thyroid lymphocyte-derived library, several show evidence of D-D fusion [56] . It is therefore possible that the thyroid is enriched for B-lymphocytes expressing heavy chains with D-D fusion, although no known mechanism would account for such enrichment in the case of non-thyroid antigen specific 'by-stander' B-lymphocytes. Alternatively, D-D fusion may be more common than previously thought. In addition, there are no conspicuous general features of the heavy-chain CDR3 sequence, either when taken together or when divided by epitope specificity, that might explain the high frequency of D-D fusion. Heavy-chain CDR3 region lengths in the TPO Ab repertoire are typical of those found in the normal adult repertoire [54, 551 . Therefore the significance of the CDR3 region in TPO Ab reactivity is still poorly understood.
Epitope mapping of TPO Abs
Two complementary systems mapping Ab reactivity to native TPO currently exist. However, it is important to note that while the nomenclature of these domain systems is identical, there is as yet no definitive study comparing the two systems. As we shall argue below, it seems likely that the A domain of one of these systems is topologically equivalent to the B domain of the other and vice versa.
A panel of murine mAbs has been described interacting with four domains (termed A to D) on native human TPO; only the binding of mAbs interacting with domains A and B was inhibited by patient serum TPO Abs [61] . In particular, one of these mAbs appears to bind to the same site on native TPO as the majority of serum TPO Abs from patients with AITD [62] . In addition, one of the mAbs, mAb#47 (interacting with domain A), shows reactivity to denatured TPO, and has been mapped to the linear C21 sequence [63, 641 . This mapping therefore potentially provides a positive localization for the immunodominant region of native TPO.
The second mapping system uses patient-derived TPO-reactive Fab; Chazenbalk et al. [19] have defined a single immunodominant region of TPO, with two neighbouring domains (A and B), each subdivided into two subdomains (Al, A2 etc.) on the basis of cross-inhibition experiments (Fig. 2 ) [19] . One Fab fragment binds to a region straddling both A and B domains. This system has been used to characterize TPO Ab reactivity, and demonstrates long-term stability of domain recognition [19, [65] [66] [67] [68] . Typically, Fab interacting with these domains inhibit >80% of patient serum TPO Ab binding (reviewed in [41] ). These Fab do not inhibit binding of the murine mAb#47 [69] , and replacement of the C21 sequence in TPO with the equivalent peptide sequence from the highly homologous enzyme myeloperoxidase (MPO) did not inhibit Fab binding [70] , leading to the conclusion that the C21 region is not the site of the immunodominant region.
Competition between our TPO Fab and the murine mAbs described above [61] shows a division in domain recognition between those Fab containing the V,012 light chain (principally recognizing the murine mAb domain B), and those not containing this light chain (principally recognizing the murine mAb domain A, B. Czarnocka, M. Janota-Bzowski, R.S. McIntosh, M.S. Asghar, P.F. Watson, E.H. Kemp, P. Carayon and A.P. Weetman, unpublished work). Two pieces of evidence suggest that both mapping systems are in fact describing the same immunodominant region. Firstly, there is the similarity of the germline V-regions used by a large number of the TPO-reactive Fab described to date, and the division of epitope binding patterns between Fab with or without VK012-derived light chains [41] . Secondly, both mapping systems are reported to inhibit the binding of the majority of TPO Ab activity to native TPO in patient sera 119, 61, 62, [65] [66] [67] [68] . Using the presence of the V,012 light chain as an important element of epitope preference, it therefore appears that epitope A described by Chazenbalk et al. [19] is topologically equivalent to epitope B described by Ruf et al. [61] and vice versa.
Given the published reactivity of the murine mAb#47 to a linear sequence of TPO (C21 in [63, 64] ), it is further possible to speculate that the immunodominant region of native TPO lies close to the mAb#47/C21 sequence. However, there is evidence against this hypothesis. Firstly, pre-incubation of TPO with TPO-reactive Fab was reported not to inhibit binding of mAb#47 [69] . However, we have noted the same phenomenon, with our TPOreactive Fab not inhibiting binding of mAb#47, whereas pre-incubation with mAb#47 did inhibit binding of TPO-reactive Fab (B. Czarnocka, M. Janota-Bzowski, R.S. McIntosh, M.S. Asghar, P.F. Watson, E.H. Kemp, P. Carayon and A.P. Weetman, unpublished work). This may be caused by the high affinity of mAb#47 [61] , or the fact that the C21 linear sequence may flank the immunodominant region, allowing access of the murine mAb to a portion of its epitope, thus facilitating displacement of Fab (B. Czarnocka, M. Janota-Bzowski, R.S. McIntosh, M.S. Asghar, P.F. Watson, E.H. Kemp, P. Carayon and A.P. Weetman, unpublished work). Secondly, in an analysis using replacement of small segments of TPO sequence with MPO sequence, replacement of the C21 sequence itself and of surrounding areas was reported not to affect the binding of TPO-reactive Fab [70] . However, it is unclear whether perturbation of a linear sequence within a conformational epitope would be expected to abolish binding completely, and the affinity of Fab for the chimaeric TPO/MPO sequences was not established. In addition, if the C21 sequence flanks the immunodominant region, replacement of this sequence would not be expected to affect Fab binding. In another study, replacement of a larger region containing the C21 sequence did prevent binding of Fab [71] , thus supporting our hypothesis.
ANTIBODIES TO THE TSH RECEPTOR
Epidemiology and pathogenicity
In GD it seems clear that the crucial factor in pathogenesis is the presence of AAb to the TSH-R, stimulating cyclic AMP accumulation and leading to hyperthyroidism and goitre (reviewed in [2, 721) . Other AITD patient groups also display reactivity towards the TSH-R, causing inhibition of binding of TSH or inhibition of receptor function; however, the nomenclature of the various TSH-R Ab activities is confused by the number of assays available and the often conflicting results from these assays [2, 731 . Almost all patients with GD have thyroid stimulating Abs (TSAb) detectable in their sera; TSH-R Abs without stimulating activity are found in 10-20% of patients with autoimmune hypothyroidism [2] . The Abs against the TSH-R therefore have different reactivities, and may be present simultaneously in the same patient [74] . Using Epstein-Barr virusimmortalization followed by limiting dilution, the frequency of peripheral blood B-cells producing IgG class TSH-R Abs has been reported as approximately 1 in 5 x lo6 B-cells [75] . The levels of TSAbs in serum are low, activities being detected due to highaffinity interactions and the use of sensitive bioassays measuring cyclic AMP release [72, 73, [76] [77] [78] , although alternative signalling pathways have been proposed (reviewed in [79] ). TSAbs are predominantly IgG1, typically with light-chain restriction Thyrotropin-binding inhibitor Igs (TBIIs) are detected by a radioligand assay, measuring the inhibition of binding of labelled TSH to the TSH-R after binding of IgG (reviewed by [72] ). TBIIs from patients with GD are predominantly IgGI, although other subclasses have been detected in a minority of patients [83] . Some Abs inhibit TSH activity in vivo and in vitro; these are termed thyroid-blocking Abs (TBAb). Whereas some TBAbs have TBII activity (i.e. act through blocking TSH binding), others do not and appear to block steps subsequent to TSH binding. The latter activity has been partially characterized using rabbit polyclonal sera to TSH-R peptides [84] . TBAbs may cause or contribute to hypothyroidism [79, 851 and are polyclonal in origin [85] . Unequivocal dissection of these various activities will result from the cloning of the various TSH-R Ab types, although progress has been made in separating the various activities using mutated forms of the TSH-R.
[80-821.
Binding sites on the TSH-R
The native structure of the TSH-R is still a matter of debate (reviewed in [2] ). Despite this, several regions of the large N-terminal extracellular domain have been investigated to determine the binding sites of TSH and TSH-R Abs, particularly by mutating regions or residues within the TSH-R, or substituting regions with those from the homologous luteinizing hormone receptor (LH-R). Replacement of residues 38-45, and in particular Cys-41, is reported to result in loss of TSH binding and TSAb activity [86] . Other TSH-R/LH-R chimaeras in which residues 21-89 are exchanged lose the ability to bind TSAb, while retaining binding of both TSH and TBAbs from patients with idiopathic myxoedema [87] . Using site-directed mutagenesis, this effect was localized to N-terminal residues 34-37, Thr-40, resides 42-45 and 52-56 [88, 891. In contrast, residues in the centre of the extracellular domain (201-222, 222-230) are reported to play a role in TSH binding alone [90, 911 . Replacement of residues 295-302, Tyr-385 or residues 387-395 with the equivalent LH-R sequence, or by mutagenesis, results in loss of TSH binding and TBAb activity, but not TSAb activity [88, 92, 931 . Several methods, including those outlined above, indicate that TSAbs from GD patients are heterogeneous in their epitope recognition, and are not all affected similarly by mutation of the different sites at the N-terminal end of the TSH-R [73, 89, [94] [95] [96] . In conclusion, TSH binding is affected by mutation of residues at various sites in the first extracellular domain, whereas TSAb activity and TBAb activity appear to act respectively at N-terminal and C-terminal sites within the extracellular region.
Molecular analysis of the TSH-R Ab response
Four reports have now been published detailing the cloning of human Abs to the TSH-R [60, [97] [98] [99] , but sequence data is only provided in one of these reports, and then only for heavy chains [60] . In that report, five Epstein-Barr virus-immortalized B-cell clones secreting TBII from one patient, and four secreting TSAbs from a second patient, are described. All clones secrete IgMrc mAbs. Although IgM Abs have been described that bind the TSH-R, it is likely that IgG Abs have far greater pathological significance [78] . In addition, the majority of TSAbs in patients with GD are A light-chain restricted, although patients have been described with K light chains displaying this activity [81, 821. Unfortunately, patient serum TSAb and TBII activities were not analysed by subclass-or light-chain-restriction in the study [60] .
Heavy-chain sequence analysis in this study indicated that the response is relatively heterogeneous [60] . The TBII clones utilized four different vH3 germline genes. This may indicate restriction, but because the vH3 family is the largest of the VH families [51, 521, it is difficult to assess the significance of this result. While three clones (one TSAb and two TBII) secreted chains derived from the VH~-23 germline region, one of these was a polymorphic sequence, with two areas of sequence insertion. There was heterogeneity of D-region usage and CDR3 sequence, and although 5 out of 9 and 3 out of 9 clones utilized the J H~ and J H~ segments respectively, these are amongst the most common in the normal adult repertoire [54, 551. The heavy chains with TBII activity showed more evidence of somatic hypermutation than those with TSAb activity, but in both cases this was substantially less than in the typical TPO repertoire. It is therefore difficult to assess how representative these sequences are of Abs with TBII or TSAb activity.
In the other three studies, mAbs were produced from patients with GD or primary myxoedema, and characterized for biological activity [97-991. IgG TSAb-secreting clones have been described from three GD patients [98] , but the TSAb activity was low considering the amounts (23-85 pg/ml) of mAbs analysed [78] . IgG-secreting lines and clones have also been described from patients with GD, before and after treatment, and from one patient with primary myxoedema [99] . Again, in this study, a large concentration of mAbs was needed for TSAb assays [78] . Interestingly, although lines rather than clones formed the bulk of the material studied, the two lines from the primary myxoedema patient displayed TSAb activity, whilst many of the lines from the Graves' patients displayed both TSAb and TBAb activity [99] .
Problems associated with the structure of the TSH-R
The generation of large amounts of purified TSH-R has long been a goal of workers in the field. Not only would this allow a degree of standardization of the various assays involved in TSH-R Ab detection, but it would also assist greatly in the isolation of TSH-R Abs, either in the screening of mAb supernatants or the selection of phage display libraries. However, this goal has been fraught with difficulties. The majority of Abs to the TSH-R are believed to interact with conformational (rather than linear) epitopes on native (i.e. non-denatured) TSH-R (reviewed by [12] ). This has placed constraints on the ability to detect and map Abs. Bacterially derived proteins and peptides may be in the wrong conformation [63, 1001 , and are also not glycosylated. Although peptides have been used to detect Abs and interfere in binding assays, they are not an ideal source of material to study conformational interactions [12] . Nevertheless, sera from around half of 20 Graves' patients tested were reported to bind bacterially derived TSH-R extracellular domains, with seven sera showing greater reactivity towards folded than unfolded material [loll. Where tested, sera preferentially recognized a tetrameric species, although the significance of this to Ab reactivity in vivo is unclear [loll. Because of the difficulties in the interpretation of experiments using TSH-R in a non-native conformation, material derived from eukaryotic expression systems has become widespread, but even here there are limitations in interpretation.
The cell-free in vitro transcription/translation system has recently been adapted for use with the TSH-R [102] . In this technique, RNA transcribed from a plasmid template is translated in vitro, using incorporation of radiolabelled amino acids to allow detection of the small amounts of protein synthesized. Because only the protein synthesized in vitro is radiolabelled, it allows analysis of the Ab response with the purest antigen preparation currently available, albeit not in its native conformation. Using this technique, Morgenthaler et al. [lo21 have studied the TSH-R Ab response using immunoprecipitation of Ab-antigen complexes, showing considerable reactivity to the protein produced by a number of GD sera, although there was no correlation with TBII. Because translation starts at internal methionine residues as well as the normal initiation site, a number of smaller protein fragments were also detected; these have allowed a degree of epitope mapping. Attempts by other groups to make TSH-R protein using in vitro transcription/translation have not resulted in material that is recognized by patient sera [103] , and the reasons for this difference remain to be explained. As well as the problems associated with conformation, a general flaw of this technique is that there is no glycosylation of the proteins produced [78] . It is therefore currently unclear whether this technique will have widespread applic-ability in the production of material for the cloning of TSH-R Abs. In addition, the relationship between the Abs reactive to TSH-R in its non-native configuration (as described in [loll and [lo21 for example) and those measured using clinical tests has still to be established.
One widely used source of material is derived from the insect cell/baculovirus system, in which the TSH-R coding region is placed downstream of the polyhedrin or basic protein promoters in baculovirus-derived vectors [73, . Both the whole TSH-R and the first extracellular domain have been produced in this way. While these proteins typically detect TSH-R Ab, only one report has described binding of TSH [107] , raising doubts as to the conformation and glycosylation of the material [106, 1081. Indeed, the TSH-R extracellular domain is secreted poorly in this system, and material has therefore been purified from whole cell extracts by immunoaffinity chromatography [lo41 and is known to have glycosylation deficiencies [78] .
The use of mammalian expression systems has also been widely adopted, using Chinese hamster ovary or monkey kidney (COS) cells. The use of Chinese hamster ovary cells in particular has become routine, with many laboratories moving to this source of recombinant TSH-R for Ab bioassays. However, even in this latter system, the structure of the TSH-R produced has been questioned [13, 781. The high-level expression vectors used appear to overwhelm the capacity of the cells to glycosylate correctly the recombinant extracellular domain of the TSH-R. This results in retention within the cell of an immature protein not bound satisfactorily by TSH or by TSH-R Abs [13, 1091 , as with the material from insect cells (see above). Glycosylation of at least two sites in the TSH-R is known to be essential for correct biological function [110] but, in addition, it appears that glycosylated chains have to reach maturity before achieving full biological activity [78] .
In the absence of the bonefide antigen, selection of phage and screening of hybridoma supernatants is less likely to succeed, and those Ab specificities selected will not necessarily be the Abs of highest affinity or greatest pathological relevance [78] . This may therefore account for the low TSAb activities of the Abs described to date. Because of the breadth of the Ab response to the TSH-R, it is clear that a considerable number of Abs will need to be sequenced and characterized extensively with regard to their activity before we begin to understand the complex interrelationships and derivation of these Abs. It is disappointing therefore that so little sequence information has been published to date on the TSH-R Abs that have been cloned.
A set of criteria has been published to which TSH-R Abs, and in particular TSAbs, must conform to be accepted as reflecting the in vivo situation [78] . These are that: (1) the Ab should be an IgG; (2) the affinity of the Ab should be in the nM range (i.e. effects should be detectable at levels of ng/ml); (3) activity should be adsorbed by specific antigen; (4) the Ab should be active after purification; and ( 5 ) the heavy-and light-chain genes should be analysed and expressed, giving the same specificity and reactivity. The Abs published to date do not meet these criteria [78] .
UNANSWERED QUESTIONS
There are a number of unanswered questions about the Ab response to thyroid antigens that can be addressed with reference to the Ab response to TPO, the best characterized to date.
Are the germline counterparts of TPO Abs TPO-specific?
McLachlan and Rapoport [41] have argued convincingly that the heavy and light chains derived from TPO-selected phage probably reflect authentic pairings from the in vivo TPO Ab response. Assuming this to be the case, the antigen specificity of the germline counterparts of these heavy-and lightchain pairings is unknown, as, with the exception of the V,012 light chain, most sequences show evidence of substantial somatic hypermutation. If these germline counterparts are indeed TPOspecific, do the germline pairings have a lower affinity, and do they form an ever reducing proportion of the TPO repertoire in patients as their somatically hypermutated sister clones expand? If the latter is the case, it would preclude their appearance in B-cell immortalization or phage display analyses of patients.
Where would germline pairings best be found?
The nature of AITD makes patient samples early in disease difficult to obtain; how do we define early disease, and would it be possible to obtain clinical samples sufficiently early to obtain the germline pairings? Given the probable low(er) affinity of such sequences for TPO, how would they best be selected or detected? Molecular engineering of such sequences to produce germline counterparts may therefore be necessary to investigate their reactivity to TPO.
Do these germline pairings show other specificities?
Evidence of cross-reactivity of the germline counterparts towards other (bacterial or viral?) antigens might provide clues as to the initiating antigen, if it is not TPO. The development, through somatic hypermutation, of higher affinity towards TPO might mask the original specificity of the germline pairings, thereby making this question impossible to answer through the analysis of the repertoire later in disease. Defining the antigen initiating the clonal expansion of these B-cells is crucial to our better understanding of the early pathogenic events, both at the B-cell and T-cell level. Carefully controlled studies in elderly women, euthyroid women with serum TPO Ab-positivity in the postpartum period, and relatives of patients with juvenile Hashimoto's thyroiditis, suggest that TPO Abs in the euthyroid controls bind to the same immunodominant domain on native TPO as patients with AITD [65-671. These studies measured levels of IgG TPO Abs: class switching to IgG implies a prolonged 'exposure' to antigen, probably also resulting in somatic hypermutation, but the repertoire in these controls may nevertheless be closer to 'germline' in composition than that in patients with established disease.
What consequences does the TPO repertoire have for the course of AITD?
This question deserves answers in two general areas: the direct role of TPO Abs in AITD pathology, and the role they may have in influencing the T-cell response. We have outlined above arguments that the Ab response to native TPO in AITD patients is localized somewhere near the linear C21 sequence. Because the direct role of TPO Abs in the pathogenesis of AITD is so poorly understood, it is unclear what the consequences of this localization are. Indeed, euthyroid individuals can mount an Ab response to this region without apparent thyroid dysfunction. Other epitopes on TPO have been described, but these are from linear sequences, and it is also unclear what pathological role Abs to these sequences might play [12] .
Ab binding to antigen is known to affect the processing and presentation of the antigen by antigenspecific B-cells [17, 181 . These B-cells are critically important in the development of an immune response because of the role they can play in concentrating specific antigens for presentation to T-cells [16] . The similarity in individual epitopes recognized in different patients may reduce the effect a B-cell-bound Ab has on heterogeneity generated by antigen processing, but it seems likely that the immunodominant region contains several distinct Ab epitopes [19, 41, 611 .
CONCLUSIONS
Of the three principle thyroid autoantigens, the Ab response to TPO is by far the best understood. Although there is evidence of antigen-selected somatic hypermutation in the reported Tg Ab sequences, there is no overall pattern of repertoire restriction. In contrast, the substantial number of sequences of TPO-reactive Abs now available suggests an important element of restriction in the TPO Ab repertoire. Whereas restriction is present at the level of the presumed germline heavy-and lightchain V-regions, there is no apparent restriction of other important elements of the Ab response, for example in CDR3 structure or sequence. However, many potential V/(D)/J recombinations might show similarity to the TPO Ab sequences described to date. Such flexibility in the repertoire would imply that recombination of Ig loci to give potentially reactive AAbs is not the rate-limiting step in the development of thyroid-reactive Abs. For the TSH-R Ab response, few Ab sequences have been described, and these are of unclear significance because of their Ig class or poor reactivity.
For TPO-reactive Abs, a clear correlation exists between light-chain V-region usage and epitope mapping, suggesting a possible localization of the immunodominant region to the area around the C21 sequence, although experiments to substantiate this are required. It is likely, however, that definitive mapping of the immunodominant domain will require co-crystallization of TPO with Fab [41] . Mutation of the TSH-R sequence has greatly enhanced our understanding of the sites with which TSH and the various TSH-R Abs interact, although the analysis of mAb interaction with the TSH-R has yet to be performed. Further investigation of Ab sequences and reactivities should enhance our understanding of the role of Tg, TPO and TSH-R Abs in thyroid autoimmunity.
